Log In
Print
BCIQ
Print
Print this Print this
 

XP21279

Also known as: XP21279 SR1

  Manage Alerts
Collapse Summary General Information
Company XenoPort Inc.
DescriptionSustained-release transported prodrug of L-dopa
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$145.0M

$20.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today